



#### United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/435,576	11/08/1999	CHIH-MING CHEN	300.1003	5401	
23280	7590 06/18/2002				
DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR			EXAMINER		
NEW YORK		JK	WILLIAMSON, MICHAEL A		
			ART UNIT	PAPER NUMBER	
			1616		
			DATE MAILED: 06/18/2002 / 7		

Please find below and/or attached an Office communication concerning this application or proceeding.

	1	Application N	0.	Applicant(s)		
055		09/435,576		CHEN ET AL.		
Office Action Summ	ary i	xaminer		Art Unit		
	1	Michael A. Will	liamson	1616		
The MAILING DATE of this of Period for Reply	communication appea	rs on the cov	er sheet with the c	orrespondence address		
A SHORTENED STATUTORY PETTHE MAILING DATE OF THIS CO  - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date of if the period for reply specified above is less the If NO period for reply is specified above, the mailing to reply within the set or extended periodary reply received by the Office later than three earned patent term adjustment. See 37 CFR 1	MMUNICATION, provisions of 37 CFR 1.136(a this communication, an thirty (30) days, a reply with aximum statutory period will a to for reply will, by statute, cate months after the mailing designed.	a). In no event, ho	owever, may a reply be tim ninimum of thirty (30) days re SIX (6) MONTHS from	ely filed s will be considered timely. the mailing date of this communication.		
1) Responsive to communicati	on(s) filed on <u>08 Jan</u>	<u>uary 2002</u> .				
2a) ☐ This action is FINAL.	2b)⊠ This a		-final.			
3) Since this application is in coclosed in accordance with the Disposition of Claims	ondition for allowand	e except for	formal matters pre	osecution as to the merits is 53 O.G. 213.		
4)⊠ Claim(s) <u>1-75</u> is/are pending	in the application.					
4a) Of the above claim(s)	is/are withdrawn	from conside	eration.			
5) Claim(s) is/are allowed						
6)⊠ Claim(s) <u>1-75</u> is/are rejected.						
7) Claim(s) is/are objecte	d to.					
8) Claim(s) are subject to		ection require	ement			
Application Papers			5 <b>5</b>			
9)☐ The specification is objected to	by the Examiner.					
10) The drawing(s) filed on	is/are: a)∏ accepted	or b) object	ted to by the Exam	iner.		
Applicant may not request that	any objection to the dra	awing(s) be he	eld in abevance. See	e 37 CFR 1.85(a)		
11)☐ The proposed drawing correcti	on filed on is:	a) approv	red b)⊡ disapprov	ed by the Examiner.		
If approved, corrected drawings	are required in reply to	this Office a	ction.			
12)☐ The oath or declaration is object	cted to by the Exami	ner.				
Priority under 35 U.S.C. §§ 119 and 12	20					
13) Acknowledgment is made of a	claim for foreign pri	ority under 3	5 U.S.C. § 119(a)-	(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ Non	e of:			( ) = ( ) =		
1. Certified copies of the p	riority documents ha	ve been rece	eived.			
				ı No.		
<ul> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) ☐ Acknowledgment is made of a c	laim for domestic pri	ority under 3	5 U.S.C. § 119(e)	(to a provisional application)		
a) The translation of the forei 15) Acknowledgment is made of a c Attachment(s)	gn language provisio	nal apolicati	on has been recei	ved.		
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Revalue       Information Disclosure Statement(s) (PTO-1)	view (PTO-948) 449) Paper No(s) <u>4&amp;11</u> .	4) [] 5) [] 6) []	Interview Summary (F Notice of Informal Pat Other: .	PTO-413) Paper No(s) ent Application (PTO-152)		
S. Palent and Trademark Office TO-326 (Rev. 04-01)	Office Action 5	Summary		Part of Paner No. 12		

Art Unit: 1616

#### **DETAILED ACTION**

#### Pending Claims

The pending claims in the instant application are 1 -75. The independent claims are 1, 48, 51, 58, 62, 70-72 and 74.

### Claim Rejections - 35 USC § 112

1. The rejection of claims 1-75 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a controlled release oral solid dosage form comprising a core of an alkyl ester of a hydroxy substituted naphthalene compound, a pharmaceutically acceptable, water swellable polymer and an osmotic agent and an outer coating layer which completely covers the core comprising a pH sensitive coating agent and a water insoluble polymer used at a weight ratio of about 0.1:1 to 0.75:1 at a combined coating weight of 0.5-5% by weight, does not reasonably provide enablement for a controlled release oral solid dosage formulation without the recited limitations regarding a core and an outer coating having the weight ratio and combined coating weight has been maintained for reasons of record in paper number 2, paragraph 2.

Art Unit: 1616

#### Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Alberts et al. (U.S. Patent 4,997,658).

Alberts et al. discloses an alkyl ester of a hydroxy substituted naphthalene derivatives, including lovastatin, which is a medicament used in lowering the plasma cholesterol level in a subject by time-controlled administration (see entire document). Alberts et al. does not disclose materials that are similar or the same as those of used in the instant claimed invention.

Oshlack et al. discloses structural components as well as compositions used to overcoat active agent including pharmaceuticals (see Abstract and entire document). The advantage of the overcoat is to protect from the environment. Therefore, it would have been obvious to one of ordinary skill in the art to use the coating compositions disclosed by Oshlack et al. in the invention of Alberts et al. to obtain an active

Application/Control Number: 09/435,576

Art Unit: 1616

ingredient that is protected from the environment to provide stability in the absence of a factual showing to the contrary or a showing of unexpected result.

4. The rejection of claims 1-75 under 35 U.S.C. 103(a) as being unpatentable over Monaghan et al. (U.S. Patent 4,231,938) in view of Oshlack et al. (U.S. Patent 5,324,351 or 5,472,712) has been withdrawn in view of Applicant's arguments.

### **Double Patenting**

5. The rejection of claims 1-75 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 5,916,595 has been withdrawn in view of Applicant's submission of a Terminal Disclaimer.

## Response to Arguments

6. Applicant's arguments filed March 9, 2001 have been fully considered but they are not persuasive.

Applicant argues that the instant claimed invention is enabled because a number of technologies are disclosed and supported by the specification (see page 2,

Application/Control Number: 09/435,576 Page 5

Art Unit: 1616

Enablement continued to page 4). Applicant is claiming an article in claims 1-47 using functional language. Applicant has named a limited number of materials that meet said limitations. It is therefore the Examiner's position that the instant claimed invention is limited to the as is determined by the materials used since it is not what additional materials meet the limitation of the functional language used.

7.

# **Crystal Mall 1 Facsimile Center**

A facsimile center has been established in Crystal Mall 1, room 7C10. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier number for accessing the facsimile machine is (703) 308-4556. The new location should be used in all instances when faxing any correspondence to Group 1600. Use of the new Crystal Mall 1 center will facilitate rapid delivery of materials to the Group. The faxing of all papers must conform with the notice published in the Official Gazette, 1096 O.G. 30 (November 15, 1989).

8. Any inquiry concerning this communication or earlier communication from the examiner should be directed to Michael A. Williamson whose telephone number is (703) 308-1235.

Michael A. Williamson Patent Examiner

Group 1610

Williamson020617 June 17, 2002